Randomized Phase II Trial Tests Nivolumab Then Nivolumab-Ipilimumab or Docetaxel
A new randomized Phase II clinical trial, OPTIM, is testing whether escalating immune therapy can improve outcomes for people with ...
A new randomized Phase II clinical trial, OPTIM, is testing whether escalating immune therapy can improve outcomes for people with ...
In a groundbreaking study published in the June 2026 issue of Oncotarget, researchers from the Dana-Farber Cancer Institute have unveiled ...
A newly published study from Karolinska Institutet has illuminated a critical factor that may undermine the effectiveness of cancer immunotherapy—neutrophils, ...
For decades, the phenomenon of T cell exhaustion in tumors has puzzled immunologists and oncologists alike. Mitochondrial dysfunction has long ...
In a groundbreaking development that challenges prevailing paradigms of cancer immunotherapy resistance, researchers have unveiled a novel intrinsic mechanism by ...
In a groundbreaking international collaboration, researchers from Moffitt Cancer Center, the Karolinska Institutet, and the University of Texas MD Anderson ...
In a dramatic revelation that challenges conventional thinking about cell biology, scientists report that cancer cells can effectively “poison” the ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine